Study of endostain combined with cisplation in malignant pleural effusion of lung cancer / 中国生化药物杂志

ABSTRACT

Objective To observe the efficacy and safety of pleural perfusion of recombinant human endostain ( endostar) combined with cisplatin ( DDP) in lung cancer patients with pleural effusion.Methods 80 patients with pleural effusion of lung cancer from January 2011 to December 2014 in our hospital were selected and randomly divided into the treatment group and the control group two groups with 40 cases in each group.Recombinant human endostain and DDP were injected into pleural cavity in the treatment group, the same dose of DDP was injected into the control group.Pleural effusion, KPS, Toxic and the exepress of vascular endothelial growth factor ( VEGF) of pleural effusion were measured before and after treatment. Results After treatment, the clinical efficacy of the observation group (RR), quality of life improvement rate and the level of VEGF in pleural effusion was significantly higher than that in the control group, the difference was statistically significant (P <0.05).The level of VEGF in Bloody pleural effusion was higher than in the non-bloody pleural effusion in the treatment group, there was significant difference (P<0.05).The observation group was higher than that of non hemorrhagic pleural effusion VEGF , the difference was statistically significant ( P <0.05 ) , both of them could lead to the decrease of VEGF level after treatmen, but there was no statistical significance between the two groups.Conclusion Clinical efficacy of intrapleural injection of recombinant human endostatin combined with cisplatin in patients with lung cancer complicated with pleural effusion, low adverse reaction, it is speculated that the recombinant human endostatin can inhibit the growth of tumor and the formation of pleural effusion by inhibiting the expression of VEGF in combination with cisplatin, it could effectively improve the quality of life of patients and prolong life.